News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Catabasis (CATB) Reports Third Quarter 2016 Financial Results And Recent Corporate Highlights



11/11/2016 12:54:40 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

-- Enrollment Complete for MoveDMD® Phase 2 Trial of Edasalonexent, a Potential Disease-Modifying Treatment for Duchenne Muscular Dystrophy (DMD) --

-- Expanding Rare Disease Pipeline with CAT-5571, a Potential Treatment for Cystic Fibrosis --

-- Investor Day Scheduled for November 17 --

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2016 and corporate highlights.

“Catabasis is executing on its mission to bring hope and life-changing therapies to patients and their families suffering from rare diseases”

“Catabasis is executing on its mission to bring hope and life-changing therapies to patients and their families suffering from rare diseases,” said Jill C. Milne, Chief Executive Officer of Catabasis. “We completed enrollment in the Phase 2 portion of the MoveDMD® clinical trial in October and expect to report top-line safety and efficacy results from the placebo-controlled portion of the trial in the first half of Q1 2017; we expect to generate a rich and informative data set in DMD based on the design of the MoveDMD trial including the 36-week open-label extension. We believe in the potential of edasalonexent as monotherapy for the treatment of DMD and also believe that a combination drug approach may be able to offer additional benefits to patients. In addition to our work in DMD, we are evaluating other diseases where the inhibition of NF-kB may be beneficial. There are a number of other rare diseases where NF-kB plays an important role and edasalonexent could have the potential to positively impact patients affected by these diseases. Further, Catabasis recently expanded its rare disease pipeline by adding CAT-5571, an activator of autophagy, as a potential treatment of cystic fibrosis.”


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES